Nurix Therapeutics Gains Ground As Roche Partnership Targets Growing B-Cell Blood Cancer Market

기사 요약

Nurix Therapeutics and Roche sign a BTK degrader partnership worth up to $2.3 billion, supporting Phase 3 plans for bexobrutideg.